نتایج جستجو برای: exemestane

تعداد نتایج: 576  

2017
Shaman Luo Gang Chen Cristina Truica Cynthia C. Baird Kim Leitzel Philip Lazarus

Exemestane (EXE) is an aromatase inhibitor used for the prevention and treatment of breast cancer. The major metabolic pathway for EXE is reduction to form the active 17β-dihydro-EXE (17β-DHE) and subsequent glucuronidation to 17β-hydroxy-EXE-17-O-β-D-glucuronide (17β-DHE-Gluc) by UGT2B17. The aim of the present study was to determine the effects of UGT2B17 copy number variation on the levels o...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2002
M Namer

• Nonsteroidal, type II (reversible) anti-aromatases, termed aromatase inhibitors. The first clinically available drug, aminoglutethimide (AG), belongs to this class. Aminoglutethimide is nonspecific and requires patients to associate a corticosteroid. Two newer, more specific agents that are administered orally and act solely on aromatase have been tested: letrozole (Let) (2.5 mg/day) and anas...

Journal: :Clinical advances in hematology & oncology : H&O 2016
Ingrid S Mayer

S6-01. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/ TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35. Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید